



# Summary of Relevant Codes for Gamifant<sup>®</sup> (emapalumab-lzsg)

Please see Important Safety Information on last page and full [Prescribing Information](#) for Gamifant.



## Summary of Relevant Codes

### ICD-10-CM Diagnosis Code<sup>1</sup>

ICD-10-CM Code	Description
D76.1	Hemophagocytic lymphohistiocytosis

### EAPG Code<sup>2</sup>

EAPG Code	Description
780	Other hematologic diagnoses

### HCPCS Code for Product<sup>3</sup>

HCPCS Code	Description
J9210	Injection, emapalumab-lzsg, 1 mg

### NDC Numbers<sup>4</sup>

NDC Numbers	Description
72171-501-01	One 10-mg/2-mL (5 mg/mL) single-dose vial
66658-505-01	One 50-mg/10-mL (5 mg/mL) single-dose vial
66658-510-01	One 100-mg/20-mL (5 mg/mL) single-dose vial

### Concomitant Medication<sup>3</sup>

HCPCS Code	Description
J1100	Dexamethasone sodium phosphate, 1 mg

EAPG=Enhanced Ambulatory Patient Group; HCPCS=Healthcare Common Procedure Coding System; ICD-10-CM=International Classification of Diseases, Tenth Revision, Clinical Modification; NDC=National Drug Code.

### Indication and Usage

Gamifant® (emapalumab-lzsg) is an interferon gamma (IFN $\gamma$ )-blocking antibody indicated for the treatment of adult and pediatric (newborn and older) patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent, or progressive disease or intolerance with conventional HLH therapy.

### Important Safety Information

Before initiating Gamifant, patients should be evaluated for infection, including latent tuberculosis (TB). Prophylaxis for TB should be administered to patients who are at risk for TB or known to have positive purified protein derivative (PPD) test result or positive IFN $\gamma$  release assay.

**Please see additional Important Safety Information on last page and full [Prescribing Information](#) for Gamifant.**

## Summary of Relevant Codes (*continued*)

### CPT Code Examples

Procedure Type	CPT Code <sup>5</sup>	Indications for Testing
<b>Administration</b>	<b>96365</b>	Therapeutic, prophylactic, and diagnostic injections and infusions
<b>Monitoring or Treatment Observation Codes</b>		
Platelet counts	<b>85049</b>	Monitoring – Lab test
WBC and differential	<b>85004</b> <b>85048</b>	Monitoring – Lab test
Ferritin	<b>82728</b>	Monitoring – Lab test
Coagulopathy (D-dimer or fibrinogen)	<b>85610</b>	Monitoring – PT/INR lab test
	<b>85730</b>	Monitoring – APTT lab test
	<b>85379</b>	Monitoring – D-dimer lab test
	<b>85384</b>	Monitoring – Fibrinogen lab test
Splenomegaly	<b>76700</b>	Ultrasound abdomen
	<b>74160</b>	Computerized tomography (CT) scan of the abdomen with contrast
	<b>74150</b>	CT scan of the abdomen without contrast
Fever (WBC)	<b>85025</b> <b>85027</b>	Complete blood count (CBC) with differential
		CBC without differential
Tuberculosis	<b>86580</b>	Skin test for tuberculosis (PPD)
	<b>86480</b>	Tuberculosis test, cell mediated immunity measurement of gamma interferon antigen response
Adenovirus	<b>87798</b>	Adenovirus DNA, qualitative, real-time PCR
Epstein Barr Virus (EBV)	<b>86664</b>	EBV immunoassay
Cytomegalovirus (CMV)	<b>87252</b> <b>87254</b>	CMV, conventional and rapid, culture

APTT=activated partial thromboplastin time; CPT=Current Procedural Terminology; PCR=polymerase chain reaction; PPD=purified protein derivative; PT/INR=prothrombin time/international normalized ratio; WBC=white blood cell count.

### Important Safety Information (*continued*)

During Gamifant treatment, patients should be monitored for TB, adenovirus, Epstein-Barr virus (EBV), and cytomegalovirus (CMV) every 2 weeks and as clinically indicated.

**Please see additional Important Safety Information on last page and full [Prescribing Information](#) for Gamifant.**

## Summary of Relevant Codes (*continued*)

### DRG/APR-DRG Codes

DRG Codes <sup>6</sup>	Description
814	Reticuloendothelial & immunity disorders W MCC
815	Reticuloendothelial & immunity disorders W CC
816	Reticuloendothelial & immunity disorders W/O CC/MCC

Medicaid APR-DRG Codes <sup>7</sup>	Description
660-1– 660-4	Major hematologic/immunologic diagnosis, except sickle cell crisis & coagulation
663-1– 663-4	Other anemias and disorders of blood and blood-forming organs

APR-DRG=All Patient Refined Diagnosis-Related Groups; DRG=Diagnosis-Related Group; W MCC=with major complications; W CC=with complications; W/O CC/MCC=without complications/major complications.

### Important Safety Information (*continued*)

Patients should be administered prophylaxis for herpes zoster, *Pneumocystis jirovecii*, and fungal infections prior to Gamifant administration.

Do not administer live or live attenuated vaccines to patients receiving Gamifant and for at least 4 weeks after the last dose of Gamifant. The safety of immunization with live vaccines during or following Gamifant therapy has not been studied.

**Please see additional Important Safety Information on last page and full [Prescribing Information](#) for Gamifant.**



#### References:

1. ICD-10 Code for hemophagocytic lymphohistiocytosis D76.1. AAPC Coder website. <https://coder.aapc.com/icd-10-codes/D76>. Accessed July 24, 2020.
2. 3M Health Information Systems. EAPG listing: effective October 1, 2018. [https://dhcf.dc.gov/sites/default/files/dc/sites/dhcf/page\\_content/attachments/DC%20EAPG%20Relative%20Weights%20Eff%2010-1-18%20DCO18023.pdf](https://dhcf.dc.gov/sites/default/files/dc/sites/dhcf/page_content/attachments/DC%20EAPG%20Relative%20Weights%20Eff%2010-1-18%20DCO18023.pdf). Published August 23, 2018. Accessed July 24, 2020.
3. Alpha-Numeric HCPCS 2020. <https://www.cms.gov/Medicare/Coding/HCPCSReleaseCodeSets/Alpha-Numeric-HCPCS-Items/2020-Alpha-Numeric-HCPCS-File>. Accessed July 24, 2020.
4. Gamifant [prescribing information]. Waltham, MA: Sobi Inc; 2020.
5. American Medical Association. *CPT® 2020 Professional Edition*. Chicago, IL: American Medical Association; 2020.
6. Diseases & disorders of blood, blood-forming organs, immunologic disorders: DRG Code Range 799-816. AAPC Coder website. <https://coder.aapc.com/drg-codes-range/17>. Accessed July 24, 2020.
7. Final APR-DRG Weights Effective July 1, 2018 (v34). New York State Department of Health website. [https://www.health.ny.gov/facilities/hospital/reimbursement/apr-drg/weights/2018-07-01\\_final\\_weights.htm](https://www.health.ny.gov/facilities/hospital/reimbursement/apr-drg/weights/2018-07-01_final_weights.htm). Accessed July 24, 2020.



## Indication and Usage

Gamifant® (emapalumab-lzsg) is an interferon gamma (IFN $\gamma$ )-blocking antibody indicated for the treatment of adult and pediatric (newborn and older) patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent, or progressive disease or intolerance with conventional HLH therapy.

## Important Safety Information

Before initiating Gamifant, patients should be evaluated for infection, including latent tuberculosis (TB). Prophylaxis for TB should be administered to patients who are at risk for TB or known to have positive purified protein derivative (PPD) test result or positive IFN $\gamma$  release assay.

During Gamifant treatment, patients should be monitored for TB, adenovirus, Epstein-Barr virus (EBV), and cytomegalovirus (CMV) every 2 weeks and as clinically indicated.

Patients should be administered prophylaxis for herpes zoster, *Pneumocystis jirovecii*, and fungal infections prior to Gamifant administration.

Do not administer live or live attenuated vaccines to patients receiving Gamifant and for at least 4 weeks after the last dose of Gamifant. The safety of immunization with live vaccines during or following Gamifant therapy has not been studied.

## Infusion-Related Reactions

Infusion-related reactions, including drug eruption, pyrexia, rash, erythema, and hyperhidrosis, were reported with Gamifant treatment in 27% of patients. In one-third of these patients, the infusion-related reaction occurred during the first infusion.

## Adverse Reactions

In the pivotal trial, the most commonly reported adverse reactions ( $\geq 10\%$ ) for Gamifant included infection (56%), hypertension (41%), infusion-related reactions (27%), pyrexia (24%), hypokalemia (15%), constipation (15%), rash (12%), abdominal pain (12%), CMV infection (12%), diarrhea (12%), lymphocytosis (12%), cough (12%), irritability (12%), tachycardia (12%), and tachypnea (12%).

Additional selected adverse reactions (all grades) that were reported in less than 10% of patients treated with Gamifant included vomiting, acute kidney injury, asthenia, bradycardia, dyspnea, gastro-intestinal hemorrhage, epistaxis, and peripheral edema.

**Please see the full [Prescribing Information for Gamifant](#).**



Gamifant is a registered trademark, owned by Sobi AG and is marketed by Sobi, Inc.  
© 2020 Swedish Orphan Biovitrum. All rights reserved. PP-9437 10/20